UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q ~~[X] Quarterly Report under Section~~

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 orOR 15(d) ~~of the Securities Exchange Act of~~OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~July 31, 2009 [ ] Transition report under Section~~June 30, 2021

☐ TRANSITION REPORT UNDER SECTION 13 orOR 15(d) ~~of the Exchange Act~~ OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

000-56090

Commission File Number: 333-151350 AIR TRANSPORT GROUP HOLDINGS, INC. (Exact name of Registrant as specified in its charter) Nevada 98-0491567 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) 7453 Woodruff Way Stone Mountain Ga 30087 Telephone: 404-671-9253 (Address of principal executive offices) (Registrant'sNumber

PHARMAGREEN BIOTECH INC.

(Exact name of registrant as specified in its charter)

Nevada

98-0491567

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

2987 Blackbear Court, Coquitlam, British Columbia BC		V3E 3A2
(Address of principal executive offices)		(Zip Code)

702-803-9404

(Registrant’s telephone number, including area code) ~~Former Name, Address and Fiscal Year, If Changed Since Last Report Check~~

Indicate by check mark whether the ~~issuer:~~registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the ~~past~~preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ~~[ ]~~☐ No ~~[X]~~

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ~~(ss.232.405~~(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☐ Yes ~~[ ]~~☐ No ~~[ ]~~

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the ~~definition~~definitions of ~~"large~~“large accelerated filer,~~" "accelerated filer"~~” “accelerated filer” and ~~"smaller~~“smaller reporting ~~company"~~company” in Rule ~~12b~~12b-2 of the Exchange ~~Act. Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ]~~ Act:

Large accelerated filer	☐	Non-accelerated filer	☐
Accelerated filer	☐	Smaller reporting company	☒
		Emerging Growth	☒

If an emerging growth company, ~~[X] (Do~~indicate by check mark if the registrant has elected not ~~check if a smaller reporting company)~~ to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ~~[ ]~~☒ No ~~[X]~~

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE ~~YEARS:~~ YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes ~~[ ]~~☐ No ~~[ ]~~

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the ~~issuer's class~~issuer’s classes of common stock, as of the latest practicable ~~date:~~ date.As of ~~October~~August 12, ~~2009, the issuer~~2021, we had ~~56,620,000~~355,831,269 shares of ~~its~~ common stock issued and outstanding.

TABLE of CONTENTS

Table of Contents

PART ~~I -~~ I—FINANCIAL INFORMATION ~~ITEM~~

Item 1. ~~FINANCIAL STATEMENTS. The interim financial statements included herein are unaudited but reflect,~~Financial Statements.

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Financial Statements

For the Nine Months Ended June 30, 2021

(Expressed in management's opinion, all adjustments, consisting only of normal recurring adjustments, that are necessary for a fair presentation of our financial position and the results of our operations for the interim periods presented. Because of the nature of our business, the results of operations for the quarterly period ended July 31, 2009 are not necessarily indicative of the results that may be expected for the full fiscal year. 2 ~~Air Transport Group Holdings, Inc. (fka Azure International, Inc.) (A Development Stage Company)~~U.S. Dollars)

(Unaudited)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Balance Sheets ~~(Stated~~

(Expressed in ~~US Dollars)~~ U.S. dollars)

	June 30, 2021			September 30, 2020
	$			$
	(Unaudited)
Assets

Current assets

Cash		19,218			12,196
Amounts receivable		88			295
Prepaid expenses and deposits		0			253,754
Total assets		19,306			266,245

Liabilities and Stockholders’ Deficit

Current liabilities

Accounts payable and accrued liabilities (Notes 3 and 7)		624,461			539,663
Advances from Alliance Growers Corp. (Note 11(a))		60,450			56,303
Due to related parties (Note 7)		607,827			508,874
Note payable (Note 4)		40,000			40,000
Convertible notes – current portion, net of unamortized discount of $Nil and $182,012, respectively (Note 5)		190,834			641,077
Derivative liabilities (Note 6)		298,301			1,380,957
Total current liabilities		1,821,873			3,166,874

Loan payable (Note 4)		32,240			30,028
Convertible notes, net of unamortized discount of $20,696 and $23,619, respectively (Note 5)		6,371			3,448
Total liabilities		1,860,484			3,200,350

Stockholders’ deficit

Preferred stock
Authorized: 1,000,000 shares, $0.001 par value; 10,000 and nil shares issued and outstanding, respectively		10			0
Common stock
Authorized: 2,000,000,000 shares, $0.001 par value; 355,129,269 and 95,806,289 shares issued and outstanding, respectively		355,129			95,806
Common stock issuable (Note 8)		121,500			180,000
Additional paid-in capital		8,628,541			3,967,261
Accumulated other comprehensive income (loss)		(31,735	)		36,679
Deficit		(10,867,990	)		(7,167,346	)
Total Pharmagreen Biotech Inc. stockholders’ deficit		(1,794,545	)		(2,887,600	)

Non-controlling interest		(46,633	)		(46,505	)

Total stockholders’ deficit		(1,841,178	)		(2,934,105	)

Total liabilities and stockholders’ deficit		19,306			266,245

As
Nature of July 31, April 30, 2009 2009 --------- --------- (Unaudited) (Audited) Assets Current assets Cash $ -- $ -- --------- --------- Total current assets -- -- --------- --------- Total Assets $ -- $ -- ========= ========= Liabilities Current liabilities Accounts payable $ 10,200 $ 8,575 --------- --------- Total current liabilities 10,200 8,575 Long term liabilities Loan from Director 6,316 2,776 --------- --------- Total Liabilities $ 16,516 $ 11,351 --------- --------- Stockholders' Equity 75,000,000 Common Shares Authorized, 56,620,000 (April 30, 2009 - 53,600,000) at $0.001 Per Share Issuedbusiness and Outstanding 56,620 53,600 Additional paid-in capital 28,630 6,400 Deficit accumulated during development stage (101,766) (71,351) --------- --------- Total stockholders equity (16,516) (11,351) --------- --------- Total liabilites and stockholders equity $ -- $ -- ========= ========= continuance of operations (Note 1)
Commitments (Note 11)
Subsequent event (Note 12)

(The accompanying notes are an integral part of these condensed consolidated financial ~~statements. 3~~ ~~Air Transport Group Holdings, Inc. (fka Azure International, Inc.) (A Development Stage Company)~~statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Operations ~~(Stated~~and Comprehensive Income (Loss)

(Expressed in ~~US Dollars)~~
For the three For the three From Inception months ended months ended (November 26, 2007) to July 31, July 31, July 31, 2009 2008 2009 ------------ ------------ ------------ Revenue $ -- $ -- $ -- ------------ ------------ ------------ Expenses General and Adminstrative Expenses 30,415 11,124 101,766 ------------ ------------ ------------ Total Expenses 30,415 11,124 101,766 Provision for Income Tax -- -- -- ------------ ------------ ------------ Net Income (Loss) $ (30,415) $ (11,124) $ (101,766) ============ ============ ============ Basic & Diluted (Loss) per Common Share (0.001) (0.000) ------------ ------------ Weighted Average Number of Common Shares 56,160,435 52,500,000 ------------ ------------
U.S. dollars)

(Unaudited)

	Three months ended June 30, 2021 $			Three months ended June 30, 2020 $			Nine months ended June 30, 2021 $			Nine months ended June 30, 2020 $

Expenses

Consulting fees (Note 7)		190,794			30,108			296,987			153,999
Foreign exchange loss (gain)		(3,044	)		(15,824	)		(16,951	)		6,025
General and administrative		20,716			28,704			64,376			91,688
Professional fees		18,829			40,068			111,788			89,915
Salaries and wages		5,085			3,858			14,753			13,005
Total expenses		232,380			86,914			470,953			354,632

Net loss before other income (expense)		(232,380	)		(86,914	)		(470,953	)		(354,632	)

Other income (expense)

Accretion of discount on convertible notes (Note 5)		(1,179	)		(54,877	)		(86,801	)		(77,889	)
Gain (loss) on change in fair value of derivative liabilities (Note 6)		101,418			(1,187,033	)		(3,083,420	)		(1,347,031	)
Gain (loss) on settlement on convertible notes (Note 5)		0			(31,898	)		613,526			(38,411	)
Interest and finance costs (Note 5)		(10,087	)		0			(673,124	)		(45,000	)
Write-off of accounts payable		0			0			0			292,557

Total other income (expense)		90,152			(1,273,808	)		(3,229,819	)		(1,215,774	)

Net loss		(142,228	)		(1,360,722	)		(3,700,772	)		(1,570,406	)

Less: net loss attributable to non-controlling interest		83			8			128			161

Net loss attributable to Pharmagreen Biotech Inc.		(142,145	)		(1,360,714	)		(3,700,644	)		(1,570,245	)

Comprehensive income (loss)

Foreign currency translation gain (loss)		(13,215	)		(17,081	)		(68,414	)		2,045

Comprehensive loss attributable to Pharmagreen Biotech Inc.		(155,360	)		(1,377,795	)		(3,769,058	)		(1,568,200	)

Basic and diluted loss per share attributable to Pharmagreen Biotech Inc. stockholders		0			(0.02	)		(0.01	)		(0.02	)

Weighted average number of shares outstanding used in the calculation of net loss per share attributable to Pharmagreen Biotech Inc.		351,763,390			82,854,083			271,420,624			78,042,762

(The accompanying notes are an integral part of these condensed consolidated financial ~~statements. 4~~ Air Transport Group Holdings, Inc. (fka Azure International, Inc.) (A Development Stage Company) STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) From Inception (November 26, 2007) to July 31, 2009 (Statedstatements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit

(Expressed in ~~US Dollars)~~
Deficit Accumulated Additional During Common Stock Paid in Development Total Shares Amount Capital Stage Equity ------ ------ ------- ----- ------ Balance at Inception, November 26, 2007 0 $ -- $ -- $ -- $ -- Shares issued for cash - February 4, 2008 at $0.0001 per share 30,000,000 30,000 (27,000) -- 3,000 Shares issued for cash - February 12, 2008 at 0.01 per share 21,000,000 21,000 -- -- 21,000 Shares issued for cash - March 11, 2008 at 0.05 per share 1,500,000 1,500 6,000 -- 7,500 Net (Loss) for period from inception (November 26, 2007) to April 30, 2008 -- -- -- (1,669) (1,669) ----------- -------- -------- ---------- --------- Balance, April 30, 2008 52,500,000 52,500 (21,000) (1,669) 29,831 =========== ======== ======== ========== ========= Shares issued from Treasury, February 1, 2009 at $0.021 per share 1,000,000 1,000 20,000 -- 21,000 Shares issued from Treasury, March 15, 2009 at $0.075 per share 100,000 100 7,400 -- 7,500 Net (Loss) for period ended April 30, 2009 -- -- -- (69,682) (69,682) ----------- -------- -------- ---------- --------- Balance, April 30, 2009 53,600,000 53,600 6,400 (71,351) (11,351) =========== ======== ======== ========== ========= Shares issued for services, May 15, 2009 at $0.0075 per share 2,000,000 2,000 13,000 -- 15,000 Shares issued for services, May 15, 2009 at $0.01 per share 1,000,000 1,000 9,000 -- 10,000 Shares issued for services, May 15, 2009 at $0.0125 per share 20,000 20 230 -- 250 Net (Loss) for period ended July 31, 2009 -- -- -- (30,415) (30,415) ----------- -------- -------- ---------- --------- Balance, July 31, 2009 56,620,000 $ 56,620 $ 28,630 $ (101,766) $ (16,516) =========== ======== ======== ========== =========
U.S. dollars)

(Unaudited)

	Preferred stock				Common stock				Common stock		Additional paid-in		Accumulated other comprehensive						Non -controlling			Total stockholders’
	Number of shares		Amount $		Number of shares		Amount $		issuable $		capital $		income (loss) $			Deficit $			interest $			deficit $

Balance, September 30, 2019		–		0		75,646,835		75,647		0		3,772,781		47,824			(4,729,476	)		(1,274	)		(834,498	)

Foreign currency translation loss		–		0		–		0		0		0		(12,399	)		0			0			(12,399	)

Net loss for the period		–		0		–		0		0		0		0			(206,021	)		(36	)		(206,057	)

Balance, December 31, 2019		–		0		75,646,835		75,647		0		3,772,781		35,425			(4,935,497	)		(1,310	)		(1,052,954	)

Issuance of common stock pursuant to the conversion of convertible notes		–		0		78,064		78		0		20,999		0			0			0			21,077

Foreign currency translation gain		–		0		–		0		0		0		31,525			0			0			31,525

Net loss for the period		–		0		–		0		0		0		0			(3,510	)		(117	)		(3,627	)

Balance, March 31, 2020		–		0		75,724,899		75,725		0		3,793,780		66,950			(4,939,007	)		(1,427	)		(1,003,979	)

Issuance of common stock pursuant to the conversion of convertible notes		–		0		15,420,104		15,420		0		126,910		0			0			0			142,330

Foreign currency translation loss		–		0		–		0		0		0		(17,081	)		0			0			(17,081	)

Net loss for the period		–		0		–		0		0		0		0			(1,360,714	)		(8	)		(1,360,722	)

Balance, June 30, 2020		–		0		91,145,003		91,145		0		3,920,690		49,869			(6,299,721	)		(1,435	)		(2,239,452	)

(The accompanying notes are an integral part of these condensed consolidated financial ~~statements. 5~~ ~~Air Transport Group Holdings, Inc. (fka Azure International, Inc.) (A Development Stage Company)~~statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of ~~Cash Flows (Stated~~Stockholders’ Deficit (continued)

(Expressed in ~~US Dollars)~~
For the three For the three From Inception months ended months ended (November 26, 2007) to July 31, July 31, July 31, 2009 2008 2009 ---------- ---------- ---------- OPERATING ACTIVITIES Net income (loss) $ (30,415) $ (11,124) $ (101,766) Non-cash adjustments Shares issued for services 25,250 -- 25,250 Accounts Payable 1,625 -- 10,200 ---------- ---------- ---------- Net cash used in operating activities (3,540) (11,124) (66,316) ---------- ---------- ---------- INVESTING ACTIVITIES -- -- -- ---------- ---------- ---------- Net cash used in investing activities -- -- -- ---------- ---------- ---------- FINANCING ACTIVITIES Common shares issued @ $0.001 per share -- -- 53,600 Additional paid-in capital -- -- 6,400 Loans From Director 3,540 -- 6,316 ---------- ---------- ---------- Net cash provided by financing activities 3,540 -- 66,316 ---------- ---------- ---------- Incease (decrese) in cash during the period -- (11,124) -- Cash at beginning of period -- 30,619 -- ---------- ---------- ---------- CASH AT END OF PERIOD $ -- $ 19,495 $ -- ========== ========== ========== Cash Paid For: Interest $ -- $ -- $ -- ========== ========== ========== Income Tax $ -- $ -- $ -- ========== ========== ========== Non-Cash Activities Shares issued in Lieu of Payment for Service $ -- $ -- $ -- ========== ========== ========== Stock issued for accounts payable $ -- $ -- $ -- ========== ========== ========== Stock issued for notes payable and interest $ -- $ -- $ -- ========== ========== ========== Stock issued for convertible debentures and interest $ -- $ -- $ -- ========== ========== ========== Convertible debentures issued for services $ -- $ -- $ -- ========== ========== ========== Warrants issued $ -- $ -- $ -- ========== ========== ========== Stock issued for penalty on default of convertible debentures $ -- $ -- $ -- ========== ========== ========== Note payable issued for finance charges $ -- $ -- $ -- ========== ========== ========== Forgiveness of note payable and accrued interest $ -- $ -- $ -- ========== ========== ==========
U.S. dollars)

(Unaudited)

	Preferred stock				Common stock				Common stock			Additional paid-in		Accumulated other comprehensive						Non -controlling			Total stockholders’
	Number of shares		Amount $		Number of shares		Amount $		issuable $			capital $		income (loss) $			Deficit $			interest $			deficit $

Balance, September 30, 2020		–		0		95,806,289		95,806		180,000			3,967,261		36,679			(7,167,346	)		(46,505	)		(2,934,105	)

Issuance of units for cash		–		0		5,400,000		5,400		0			21,600		0			0			0			27,000

Issuance of preferred shares for cash		10,000		10		–		0		0			0		0			0			0			10

Issuance of common stock pursuant to the conversion of convertible notes		–		0		144,315,380		144,316		(180,000	)		1,647,737		0			0			0			1,612,053

Issuance of common stock for services		–		0		90,000		90		0			1,265		0			0			0			1,355

Foreign currency translation loss		–		0		–		0		0			0		(42,455	)		0			0			(42,455	)

Net loss for the period		–		0		–		0		0			0		0			(417,109	)		(1	)		(417,110	)

Balance, December 31, 2020		10,000		10		245,611,669		245,612		0			5,637,863		(5,776	)		(7,584,455	)		(46,506	)		(1,753,252	)

Issuance of units for cash		–		0		17,411,250		17,411		6,113			72,701		0			0			0			96,225

Issuance of common stock pursuant to the conversion of convertible notes		–		0		84,845,100		84,845		0			2,848,372		0			0			0			2,933,217

Issuance of common stock for services		–		0		300,000		300		0			7,020		0			0			0			7,320

Foreign currency translation loss		–		0		–		0		0			0		(12,744	)		0			0			(12,744	)

Net loss for the period		–		0		–		0		0			0		0			(3,141,390	)		(44	)		(3,141,434	)

Balance, March 31, 2021		10,000		10		348,168,019		348,168		6,113			8,565,956		(18,520	)		(10,725,845	)		(46,550	)		(1,870,668	)

Issuance of units for cash		–		0		6,961,250		6,961		(6,113	)		62,585		0			0			0			63,433

Shares issuable for services		–		0		–		0		121,500			0		0			0			0			121,500

Foreign currency translation loss		–		0		–		0		0			0		(13,215	)		0			0			(13,215	)

Net loss for the period		–		0		–		0		0			0		0			(142,145	)		(83	)		(142,228	)

Balance, June 30, 2021		10,000		10		355,129,269		355,129		121,500			8,628,541		(31,735	)		(10,867,990	)		(46,633	)		(1,841,178	)

(The accompanying notes are an integral part of these condensed consolidated financial ~~statements. 6~~ ~~AIR TRANSPORT GROUP HOLDINGS~~statements)

Table of Contents

PHARMAGREEN BIOTECH INC. ~~(fka Azure International, Inc.) (A Development Stage Company) Footnotes~~

Condensed Consolidated Statements of Cash Flows

(Expressed in U.S. dollars)

(Unaudited)

	Nine months ended June 30, 2021 $			Nine months ended June 30, 2020 $

OPERATING ACTIVITIES

Net loss		(3,700,772	)		(1,570,406	)

Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on convertible notes		86,801			77,889
Financing fees and default penalties		673,124			45,000
Loss on change in fair value of derivative liabilities		3,083,420			1,347,031
Loss (gain) on settlement of convertible notes		(613,526	)		38,411
Shares issued or issuable for services		130,175			0
Write-off of accounts payable		0			(292,557	)

Changes in operating assets and liabilities:
Amounts receivable		207			9,849
Prepaid expenses and deposits		3,754			(236,798	)
Accounts payable and accrued liabilities		120,273			21,189
Due to related parties		65,307			13,840

Net cash used in operating activities		(151,237	)		(546,552	)

FINANCING ACTIVITIES

Proceeds from issuance of convertible notes		0			570,080
Proceeds from units issued and issuable for cash		186,725			0
Proceeds from issuance of preferred shares		10			0
Repayment of loans from related parties		0			(128,813	)
Proceeds from related party loans		33,646			64,981
Proceeds from loans payable		0			29,388
Financing costs		0			(5,000	)

Net cash provided by financing activities		220,381			530,636

Effect of foreign exchange rate changes on cash		(62,122	)		(12,184	)

Change in cash		7,022			(28,100	)

Cash, beginning of period		12,196			62,682

Cash, end of period		19,218			34,582

Non-cash investing and financing activities:

Original issue discount on convertible notes		0			532,594
Common shares issued for settlement of convertible notes		4,545,270			163,407
Issuance of promissory note as a financing fee		0			40,000

Supplemental disclosures:
Interest paid		0			4,601
Income taxes paid		0			0

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements ~~From Inception to July 31, 2009 (Stated~~

June 30, 2021

(Expressed in ~~US Dollars) NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Air Transport Group Holdings, Inc (the "Company"~~U.S. dollars)

(unaudited)

Nature of Business and Continuance of Operations

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of the State of Nevada, U.S. on November 26, 2007, under the name Azure International, Inc. On October 30, 2008, and effective as of the same date, the Company filed Articles of Merger (“Articles”) with the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc. The Company was previously in the business of providing technical advisory and appraisals to the aircraft and aviation business as well as providing sourcing for aircraft leases and parts. Pursuant to a Share Exchange Agreement with WFS Pharmagreen Inc. (“WFS”) on May 2, 2018, the Company changed its name to Pharmagreen Biotech Inc. and changed its principal business to the production of starter plantlets for the North American high CBD hemp and medical cannabis industries through the application of the proprietary plant tissue culture in vitro process called “Chibafreen”. This proprietary process will produce plantlets that will be genetically identical and free of pests and disease free with consistent and certifiable constituent properties.

Going Concern

These condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at June 30, 2021, the Company has not earned any revenues from operations, has a working capital deficit of $1,802,567, and has an accumulated deficit of $10,867,990. During the nine months ended June 30, 2021, the Company incurred a net loss of $3,700,644 and used cash flows for operations of $151,237. In addition, the Company filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. Refer to Note 11. As a result of the voluntary petition, various convertible note holders triggered default provisions on the Company’s outstanding convertible notes. On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company from its Chapter 11 bankruptcy proceedings and protection. Furthermore, the Company has defaulted on other convertible notes. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. Specifically, the Company attributes the pandemic to a delay in a planned financing which was to be used for the construction of the biotech complex, resulting in an impairment of the capitalized construction-in-progress at September 30, 2020. The extent to which the COVID-19 pandemic further impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its impact on the Company. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources, and financial results.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

2.	Significant Accounting Policies

	(a)	Interim Financial Statements

		These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

	(b)	Basis of Presentation

		The accompanying condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 B.C. Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

	(c)	Use of Estimates and Judgments

		The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of share-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period and in the factors regarding the impairment of the property and equipment. The Company tests property and equipment for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

	(d)	Recently Adopted Accounting Pronouncements

		The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

3.	Accounts Payable and Accrued Liabilities

	Accounts payable and accrued liabilities consists of the following:

	June 30, 2021 $		September 30, 2020 $

Accounts payable (Note 7)		550,871		455,310
Accrued interest payable (Notes 4 and 5)		73,590		84,353

		624,461		539,663

4.	Note and Loan Payable

	(a)	On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement (Refer to Note 11(b)). The promissory note is unsecured, was due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. At June 30, 2021, the Company has recorded accrued interest payable of $6,404 (September 30, 2020 - $3,421) and the promissory note is in default. On March 10, 2021, this noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court.

	(b)	On April 22, 2020, the Company received a loan for Cdn$40,000from the Government of Canada under the Canada Emergency Business Account program (“CEBA”). As at June 30, 2021, the balance owing is $32,240 (Cdn$40,000) (September 30, 2020 – $30,028 (Cdn$40,000)). These funds are interest free until December 31, 2022, at which time the remaining balance will convert to a 3-year term loan at an interest rate of 5% per annum. If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000.

5.	Convertible Notes

(a)

On April 4, 2018, the amount of $32,485 owed to related parties was converted to Series A convertible notes, which are unsecured, non-interest bearing, and due on April 4, 2023. These notes are convertible in whole or in part, at any time until maturity, to common shares of the Company at $0.0001 per share. The outstanding balance remaining at maturity shall bear interest at 12% per annum until fully paid. The Company evaluated the convertible notes for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options. The Company determined that the conversion price was below the closing stock price on the commitment date, and the convertible notes contained a beneficial conversion feature. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $32,485 as additional paid-in capital and reduced the carrying value of the convertible note to $nil. The carrying value will be accreted over the term of the convertible notes up to their face value of $32,485.

During the year ended September 30, 2018, the Company issued 31,745,000 shares of common stock upon the conversion of $3,175 of Series A convertible notes, which included 18,000,000 common shares to the President of the Company and 5,320,000 common shares to family members of the President of the Company. Upon conversion, the Company immediately recognized the related remaining debt discount of $3,112 as accretion expense.

During the year ended September 30, 2019, the Company issued 3,900,000 shares of common stock upon the conversion of $390 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $375 as accretion expense.

During the year ended September 30, 2020, the Company issued 18,525,000 shares of common stock upon the conversion of $1,853 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $1,670 as accretion expense.

As at June 30, 2021, the carrying value of the convertible notes was $6,371 (September 30, 2020 – $3,448) and had an unamortized discount of $20,696 (September 30, 2020 - $23,619). During the nine months ended June 30, 2021, the Company recorded accretion expense of $2,923 (2020 - $1,358).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

	(b)	On October 1, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,255 was paid directly to third parties for financing costs, resulting in net proceeds to the Company of $74,745. The note is due on October 1, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note.The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $70,744. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,245 and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000.

		On July 22, 2020, the Company received a preliminary statement of claim from the note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the note holder requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal in the sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note. Upon default, the Company recognized the remaining debt discount of $46,904 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $77,500 and a default penalty of $85,864. During the nine months ended June 30, 2021, the Company recorded an additional $253,856 of default penalties. During the nine months ended June 30, 2021, the Company issued 133,226,100 shares of common stock upon the conversion of $417,719 of the convertible note and $11,000 of conversion fees. On March 12, 2021, the Company entered into a settlement agreement with the noteholder. Pursuant to the agreement, the Company was required to honour various conversion notices and the noteholder agreed to waive all principal, interest and penalties incurred. As at March 12, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $163,864) and the fair value of the derivative liability was $nil (September 30, 2020 - $485,863).

	(c)	On October 17, 2019, the Company entered into a convertible note with an unrelated party for $63,000, of which $3,000 was paid directly to third parties for financing costs, resulting in net cash proceeds to the Company of $60,000. The note is due on October 17, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

		On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal balance of $63,000, and accrued interest owing on the note of $5,775 which was due on September 30, 2020. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $1,657. On September 30, 2020, the Company failed to meet the repayment terms within the settlement agreement which resulted in a default penalty of $63,000 and the resumption of the convertibility feature at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $112,822. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $63,000. During the nine months ended June 30, 2021, the Company issued 7,730,486 shares of common stock upon the conversion of $126,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $126,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $112,822).

	(d)	On January 2, 2020, the Company entered into a convertible note with an unrelated party for $53,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $50,000. The note is due on January 2, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date.

		On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $53,000 and accrued interest owing on the note. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $2,286. Effective September 30, 2020, the Company failed to meet the repayment terms of the settlement agreement and defaulted on the convertible note. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $139,702. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $53,000. During the nine months ended June 30, 2021, the Company issued 16,994,905 shares of common stock upon the conversion of $106,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $106,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $139,702).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

	(e)	On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid for financing costs, resulting in net proceeds to the Company of $75,000. The note is due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $76,330. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,500, resulting in a loss on change in fair value of derivative liabilities of $1,830, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $16,447. During the nine months ended June 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees. On January 14, 2021, the Company failed to repay the note upon maturity and recorded additional default principal of $53,007. As at June 30, 2021, the carrying value of the convertible note was $112,084 (September 30, 2020 - $16,947), net of an unamortized discount of $nil (September 30, 2020 - $61,053), and the fair value of the derivative liability was $170,586 (September 30, 2020 - $110,604).

	(f)	On January 15, 2020, the Company entered into a convertible note with an unrelated party for $61,000, of which $7,400 was paid directly to third parties for financing costs and an original issue discount of $3,000, resulting in proceeds to the Company of $50,600. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $67,846.

		The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $50,100, resulting in a loss on change in fair value of derivative liabilities of $17,746, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $61,000. On July 23, 2020, the Company entered into a settlement agreement with the note holder, wherein the Company and the lender agreed to settle a convertible note and accrued interest for a total of $63,440 on a non-convertible basis, of which $15,000 was payable on or before July 24, 2020 (paid), followed by 6 monthly instalment payments of $8,073. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $56,566. Effective August 24, 2020, the Company failed to meet the repayment terms and defaulted on the settlement agreement. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $60,500. During the nine months ended June 30, 2021, the Company issued 3,601,718 shares of common stock upon the conversion of $46,000 of the convertible note, $5,586 of accrued interest and $500 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $46,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $69,320).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

	(g)	On January 15, 2020, the Company entered into a convertible note with an unrelated party for $55,000, of which $2,500 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $52,500. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $61,173. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $52,000, resulting in a loss on change in fair value of derivative liabilities of $9,173, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $55,000.

		During the year ended September 30, 2020, the Company defaulted on the convertible note which resulted in a default penalty of $27,500 and the amendment of the conversion rate from 65% to 50% of the lowest trading price during the 20 consecutive trading days prior to conversion. The Company recognized the remaining debt discount of $50,767 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $54,500 and a default penalty of $27,500. During the nine months ended June 30, 2021, the Company issued 17,557,925 shares of common stock upon the conversion of $82,500 of the convertible note, $7,693 of accrued interest and $3,000 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $82,500) and the fair value of the derivative liability was $nil (September 30, 2020 - $146,272).

	(h)	On January 21, 2020, the Company entered into a convertible note with an unrelated party for $66,150, of which $7,800 was paid directly to third parties for financing costs and an original issue discount of $3,150, resulting in proceeds to the Company of $55,200. The note is due on January 21, 2021, and bears interest on the unpaid principal balance at a rate of 8% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $71,278.

		The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $54,700, resulting in a loss on change in fair value of derivative liabilities of $16,578, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $66,150.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $13,202. During the nine months ended June 30, 2021, the Company issued 4,431,963 shares of common stock upon the conversion of $66,150of the convertible note and $3,907 of accrued interest. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $13,702), net of an unamortized discount of $nil (September 30, 2020 - $52,448), and the fair value of the derivative liability was $nil (September 30, 2020 - $98,579).

	(i)	On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note is due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity. As at June 30, 2021, the carrying value of the convertible note was $78,750 (September 30, 2020 - $78,750) and the fair value of the derivative liability was $127,715 (September 30, 2020 - $107,660).

	(j)	On February 4, 2020, the Company entered into a convertible note with an unrelated party for $100,000, of which $16,970 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $83,030. The note is due on February 4, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $125,640. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $82,530, resulting in a loss on change in fair value of derivative liabilities of $43,110, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $100,000.

		During the year ended September 30, 2020, the noteholder converted $24,175 of the convertible note for 2,000,000 common shares with a fair value of $180,000 and was issued on October 20, 2020. Upon the notice of conversion, the Company immediately recognized the related remaining debt discount of $23,136 as accretion expense. The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $7,854.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

During the nine months ended June 30, 2021, the Company issued 41,017,383 shares of common stock upon the conversion of $75,825 of the convertible note, $2,154 of accrued interest and $18,750 of fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $7,314), net of an unamortized discount of $nil (September 30, 2020 - $68,511), and the fair value of the derivative liability was $nil (September 30, 2020 - $110,135).

6.	Derivative Liabilities

	The embedded conversion option of certain of the Company’s convertible notes described in Note 5 contain a conversion feature that qualifies for embedded derivative classification. The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities:

	$
Balance, September 30, 2020	1,380,957

Conversion of convertible notes	(4,166,076	)
Change in fair value	3,083,420

Balance, June 30, 2021	298,301

The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities as their fair values were determined by using a binomial model based on various assumptions. Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the weighted-average assumptions used in the calculations:

Expected

volatility

Risk-free interest

rate

Expected dividend

yield

Expected life

(in years)

As at June 30, 2021

256

0.1

0.5

7.	Related Party Transactions

	(a)	As at June 30, 2021, the Company owed $548,586 (Cdn$680,628) (September 30, 2020 - $453,697(Cdn$604,366)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2021, the Company incurred consulting fees of $72,171 (2020 - $63,044) to the President of the Company.

	(b)	As at June 30, 2021, the Company owed $59,241 (Cdn$73,500) (September 30, 2020 - $55,177 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand.

	(c)	As at June 30, 2021, the Company owed $27,565 (Cdn$34,200) (September 30, 2020 – $25,674 (Cdn$34,000)) to a company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand.

	(d)	As at June 30, 2021, the Company owed $431,105 (Cdn$534,870) (September 30, 2020 – $347,229 (Cdn$462,540)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2021, the Company incurred consulting fees of $72,171 (2020 - $63,044) to the company controlled by the Chief Financial Officer of WFS.

	(e)	On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a director of the Company for proceeds of $10.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

8.	Common Stock

	Nine months ended June 30, 2021

	(a)	In December 2020, the Company issued 5,400,000 units at $0.005 per unit for proceeds of $27,000 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(b)	Between January 11 to February 16, 2021, the Company issued 16,800,000 units at $0.005 per unit for proceeds of $84,000 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(c)	On March 1, 2021, the Company issued 611,250 units at $0.01 per unit for proceeds of $6,112 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(d)	During the nine months ended June 30, 2021, the Company issued 133,226,100 shares of common stock upon the conversion of $417,719 of the convertible note and $11,000 of conversion fees (Note 5(b)).

	(e)	During the nine months ended June 30, 2021, the Company issued 7,730,486 shares of common stock upon the conversion of $126,000 of the convertible note and $3,150 of accrued interest (Note 5(c)).

	(f)	During the nine months ended June 30, 2021, the Company issued 16,994,905 shares of common stock upon the conversion of $106,000 of the convertible note and $2,650 of accrued interest (Note 5(d)).

	(g)	During the nine months ended June 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees (Note 5(e)).

	(h)	During the nine months ended June 30, 2021, the Company issued 3,601,718 shares of common stock upon the conversion of $46,000 of the convertible note, $5,586 of accrued interest and $500 of conversion fees (Note 5(f)).

	(i)	During the nine months ended June 30, 2021, the Company issued 17,557,925 shares of common stock upon the conversion of $82,500 of the convertible note, $7,693 of accrued interest and $3,000 of conversion fees (Note 5(g)).

	(j)	During the nine months ended June 30, 2021, the Company issued 4,431,963 shares of common stock upon the conversion of $66,150 of the convertible note, $3,907 of accrued interest (Note 5(h)).

	(k)	During the nine months ended June 30, 2021, the Company issued 41,017,383 shares of common stock upon the conversion of $75,825 of the convertible note, $2,154 of accrued interest and $18,750 of fees (Note 5(j)).

	(l)	On November 1, 2020, the Company issued 22,500 shares of common stock with a fair value of $401 for management consulting and strategic business advisory services.

	(m)	On November 26, 2020, the Company issued 45,000 shares of common stock with a fair value of $733 for management consulting and strategic business advisory services.

	(n)	On December 11, 2020, the Company issued 22,500 shares of common stock with a fair value of $221 for management consulting and strategic business advisory services.

	(o)	On February 2, 2021, the Company issued 150,000 shares of common stock with a fair value of $2,700 for management consulting and strategic business advisory services.

	(p)	On March 29, 2021, the Company issued 150,000 shares of common stock with a fair value of $4,620 for management consulting and strategic business advisory services.

	(q)	As at September 30, 2020, the Company received a conversion notice for 2,000,000 shares of common stock with a fair value of $180,000 pursuant to the conversion of $30,750 of a convertible note (see Note 5(j)). The common shares were issued on October 20, 2020.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

8.	Common Stock (continued)

	Nine months ended June 30, 2021 (continued)

	(r)	On May 14, 2021, the Company issued 611,250 units at $0.01 per unit for proceeds of $6,113 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(s)	On May 14, 2021, the Company issued 6,350,000 units at $0.01 per unit for proceeds of $63,500. Each unit is comprised of one share of common stock and one share purchase warrant exercisable at $0.05 per share of common stock expiring 24 months from the date of issuance.

	(t)	As at June 30, 2021, the Company agreed to issue 6,750,000 shares of common stock with a fair value of $121,500, which has been included in shares issuable, pursuant to a production agreement (Note 11(d)).

Preferred Stock

On October 13, 2020, the Company filed a certificate of amendment to its articles of incorporation, whereby it increased the authorized capital to 2,000,000,000 shares of common stock with a par value of $0.001 per share and 1,000,000 preferred shares with a par value of $0.001. On October 14, 2020, the Company designated 10,000 preferred shares as Series A Super Voting Preferred Stock.

The Series A Super Voting Preferred Stock has the following rights and restrictions:

Dividends - Initially, there will be no dividends due or payable on the Series A Super Voting Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.

Liquidation and Redemption Rights - Upon the occurrence of a Liquidation Event, the holders of Series A Super Voting Preferred Stock are entitled to receive net assets on a pro-rata basis. Each holder of Series A Super Voting Preferred Stock is entitled to receive ratably any dividends declared by the Board, if any, out of funds legally available for the payment of dividends.

Rank - All shares of the Series A Super Voting Preferred Stock shall rank (i) senior to the Corporation’s (A) Common Stock, par value $0.001 per share ( “Common Stock” ), and any other class or series of capital stock of the Corporation hereafter created, except as otherwise provided in clauses (ii) and (iii) of this Section 4, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series A Super Voting Preferred-Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series A Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.

Voting Rights - If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting.

Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:

· [twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A, Series A and any newly designated Preferred stock issued and outstanding at the time of voting}] Divided by:

· [the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]

With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

Preferred Stock (continued)

Protective Provisions - So long as any shares of Series A Super Voting Preferred Stock are outstanding, the Corporation shall not, without first obtaining the unanimous written consent of the holders of Series A Super Voting Preferred Stock, alter or change the rights, preferences or privileges of the Series A Super Voting Preferred so as to affect adversely the holders of Series A Super Voting Preferred Stock.

On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a Director of the Company for proceeds of $10. In connection with the issuance of the Series A Super Voting Preferred Stock, the Company evaluated whether the preferred stock should be classified as a liability based on the guidance under ASC 480, Distinguishing Liabilities from Equity. The Series A Super Voting Preferred Stock are not considered mandatorily redeemable, are not settleable in a variable number of shares, and do not contain any features embedded that required a separate assessment. As a result, the Company determined the Series A Super Voting Preferred Stock were not a liability and classified the preferred stock within equity in the amount of the aggregate par value of the issued shares of preferred stock, with any excess attributed to additional paid-in capital.

10.	Share Purchase Warrants

	The following table summarizes the continuity of the Company’s share purchase warrants:

	Number of warrants		Weighted average exercise price $

Balance, September 30, 2020		114,286		0.55

Issued		29,772,500		0.05

Balance, June 30, 2021		29,886,786		0.05

As at June 30, 2021, the following share purchase warrants were outstanding:

Number of warrants		Exercise price		Expiry date

	114,286	$	0.55	July 16, 2022
	400,000	$	0.05	December 2, 2022
	3,000,000	$	0.05	December 11, 2022
	2,000,000	$	0.05	December 30, 2022
	2,300,000	$	0.05	January 11, 2023
	13,500,000	$	0.05	January 30, 2023
	1,000,000	$	0.05	February 16, 2023
	611,250	$	0.05	March 1, 2023
	6,961,250	$	0.05	May 14, 2023

	29,886,786

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

11.

Commitments

	(a)	Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. The second option expired unexercised. As at June 30, 2021, the Company received advances of $60,450 (Cdn$75,000) (September 30, 2020 - $56,303 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand.

	(b)	On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 4(a)). In addition, the third party is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing.

	(c)	On December 13, 2020, the Company entered into a consulting agreement with a six month term. Pursuant to the agreement, the Company will 75,000 shares of common stock per month in exchange for consulting services. On June 13, 2021, the Company extended the consulting agreement for an additional six month term for the issuance of 117,000 common shares per month. Refer to Note 12(a).

	(d)	Effective May 13, 2021, the Company entered into a production agreement with New to the Street Group LLC. Pursuant to the terms of the agreement, New to the Street Group LLC will provide investor relations and consulting services for a period of six months. Pursuant to the agreement,the Company agreed to pay New to the Street Group LLC $3,500 upon signing, $3,500 per month and 6,750,000 restricted shares of the Company’s common stock. At June 30, 2021, the 6,750,000 restricted shares of common stock have not been issued.

	(e)	Effective May 14, 2021, the Company entered into a Software as a Service Agreement with Novation Solutions Inc. (“DealMaker”) to effect the Company’s planned Regulation A offering, including the set-up of an automated tracking, signing, and reconciliation portal. The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 payable within 30 days of launching the portal, and a post launch monthly fee of $1,000.

12.

Subsequent Events

	(a)	On July 13, 2021, the Company issued 702,000 common shares for consulting services. Refer to Note 11(c).

	(b)	Subsequent to the nine months ended June 30, 2021, the Company received common stock subscriptions totaling $56,000 in connection with the proposed issuance of 5,600,000 shares of common stock at $0.01 per unit. Each unit will be comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This section of the Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Company History Overview

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of Nevada, U.S. on November 26, 2007 under the name Azure International, Inc. On October 30, 2008 and effective as of the same date, the Company filed Articles of Merger ~~("Articles")~~ with the Secretary ~~of State~~ of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation incorporated on October 16, 2008, and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.

On ~~March 10, 2009,~~April 12, 2018, the Company ~~completed~~entered into a ~~forward stock split of its common stock on a ratio of ten shares for every one~~ share of the Company. The record date of the forward stock split was February 27, 2009, the payment date of the forward split was March 9, 2009, and the ex-dividend date of the forward split was March 10, 2009. The forward split was payable as a dividend, thereby requiring no action by shareholders, nor any amendment to the articles of incorporation of the Company. The Company is in the development stage as defined under Statement on Financial Accounting Standards No. 7, Development Stage Enterprises ("SFAS No.7"). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. For the period from inception, November 26, 2007 through July 31, 2009 the Company has accumulated losses of $101,766. The company is in the airline business as an independent consultant and contractor. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. Accounting Method The Company's financial statements are prepared using the accrual method of accounting. The Company has elected an April 30 year-end. b. Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, goods delivered, the contract price is fixed or determinable, and collectability is reasonably assured. c. Income Taxes The Company prepares its tax returns on the accrual basis. The Company accounts for income taxes under the Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("Statement 109"). Under Statement 109, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial 7 statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under Statement 109, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. d. Use of Estimates The preparation of the financial statements in conformityexchange agreement with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. e. Assets The company has no cash as of July 31, 2009. f. Income Income represents all of the Company's revenue less all its expenses in the period incurred. The Company has no revenues as of July 31, 2009 and has paid expenses of $101,766 since inception. For the period ended July 31, 2009 it has incurred expenses of $30,415. g. Recent Account Pronouncements June 2009, the FASB issued SFAS No. 166, "Accounting for Transfers of Financial Assets--an amendment of FASB Statement No. 140" ("SFAS 166"). The provisions of SFAS 166, in part, amend the derecognition guidance in FASB Statement No. 140, eliminate the exemption from consolidation for qualifying special-purpose entities and require additional disclosures. SFAS 166 is effective for financial asset transfers occurring after the beginning of an entity's first fiscal year that begins after November 15, 2009. The Company does not expect the provisions of SFAS 166 to have a material effect on the financial position, results of operations or cash flows of the Company. In June 2009, the FASB issued SFAS No. 167, "Amendments to FASB Interpretation No. 46(R) ("SFAS 167"). SFAS 167 amends the consolidation guidance applicable to variable interest entities. The provisions of SFAS 167 significantly affect the overall consolidation analysis under FASB Interpretation No. 46(R). SFAS 167 is effective as of the beginning of the first fiscal year that begins after November 15, 2009. SFAS 167 will be effective for the Company beginning in 2010. The Company does not expect the provisions of SFAS 167 to have a material effect on the financial position, results of operations or cash flows of the Company. In June 2009, the FASB issued SFAS No. 168, "The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles - a replacement of FASB Statement No. 162" ("SFAS No. 168"). Under SFAS No. 168 the "FASB Accounting Standards Codification" ("Codification") will become the source of authoritative U. S. GAAP to be applied by nongovernmental entities. Rules and interpretive releases of the Securities and Exchange Commission ("SEC") under authority of federal securities laws 8 are also sources of authoritative GAAP for SEC registrants. SFAS No. 168 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. On the effective date, the Codification will supersede all then-existing non-SEC accounting and reporting standards. All other non-grandfathered non-SEC accounting literature not included in the Codification will become non-authoritative. SFAS No. 168 is effective for the Company's interim quarterly period beginning July 1, 2009. The Company does not expect the adoption of SFAS No. 168 to have an impact on the financial statements. In June 2009, the Securities and Exchange Commission's Office of the Chief Accountant and Division of Corporation Finance announced the release of Staff Accounting Bulletin (SAB) No. 112. This staff accounting bulletin amends or rescinds portions of the interpretive guidance included in the Staff Accounting Bulletin Series in order to make the relevant interpretive guidance consistent with current authoritative accounting and auditing guidance and Securities and Exchange Commission rules and regulations. Specifically, the staff is updating the Series in order to bring existing guidance into conformity with recent pronouncements by the Financial Accounting Standards Board, namely, Statement of Financial Accounting Standards No. 141 (revised 2007)WFS Pharmagreen Inc., Business Combinations, and Statement of Financial Accounting Standards No. 160, Non-controlling Interests in Consolidated Financial Statements. The statements in staff accounting bulletins are not rules or interpretations of the Commission, nor are they published as bearing the Commission's official approval. They represent interpretations and practices followed by the Division of Corporation Finance and the Office of the Chief Accountant in administering the disclosure requirements of the Federal securities laws. In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments. This FSP amends FASB Statement No. 107, Disclosures about Fair Value of Financial Instruments, to require disclosures about fair value of financial instruments for interim reporting periods of publicly traded companies as well as in annual financial statements. This FSP also amends APB Opinion No. 28, Interim Financial Reporting, to require those disclosures in summarized financial information at interim reporting periods. This FSP shall be effective for interim reporting periods ending after June 15, 2009. The Company does not have any fair value of financial instruments to disclose. In April 2009, the FASB issued FSP No. FAS 115-2 and FAS 124-2, Recognition and Presentation of Other-Than-Temporary Impairments. This FSP amends the other-than-temporary impairment guidance in U.S. GAAP for debt securities to make the guidance more operational and to improve the presentation and disclosure of other-than-temporary impairments on debt and equity securities in the financial statements. The FSP does not amend existing recognition and measurement guidance related to other-than-temporary impairments of equity securities. The FSP shall be effective for interim and annual reporting periods ending after June 15, 2009. The Company currently does not have any financial assets that are other-than-temporarily impaired. In April 2009, the FASB issued FSP No. FAS 141(R)-1, Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies, to address some of the application issues under SFAS 141(R). The FSP deals with the initial recognition and measurement of an asset acquired or a liability assumed in a business combination that arises from a contingency provided the asset or liability's fair value on the date of 9 acquisition can be determined. When the fair value can-not be determined, the FSP requires using the guidance under SFAS No. 5, Accounting for Contingencies, and FASB Interpretation (FIN) No. 14, Reasonable Estimation of the Amount of a Loss. This FSP was effective for assets or liabilities arising from contingencies in business combinations for which the acquisition date is on or after January 1, 2009. The adoption of this FSP has not had a material impact on our financial position, results of operations, or cash flows during the six months ended June 30, 2009. In April 2009, the FASB issued FSP No. FAS 157-4, "Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly" ("FSP FAS 157-4"). FSP FAS 157-4 provides guidance on estimating fair value when market activity has decreased and on identifying transactions that are not orderly. Additionally, entities are required to disclose in interim and annual periods the inputs and valuation techniques used to measure fair value. This FSP is effective for interim and annual periods ending after June 15, 2009. The Company does not expect the adoption of FSP FAS 157-4 will have a material impact on its financial condition or results of operation. In October 2008, the FASB issued FSP No. FAS 157-3, "Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active," ("FSP FAS 157-3"), which clarifies application of SFAS 157 in a market that is not active. FSP FAS 157-3 was effective upon issuance, including prior periods for which financial statements have not been issued. The adoption of FSP FAS 157-3 had no impact on the Company's results of operations, financial condition or cash flows. In December 2008, the FASB issued FSP No. FAS 140-4 and FIN 46(R)-8, "Disclosures by Public Entities (Enterprises) about Transfers of Financial Assets and Interests in Variable Interest Entities." This disclosure-only FSP improves the transparency of transfers of financial assets and an enterprise's involvement with variable interest entities, including qualifying special-purpose entities. This FSP is effective for the first reporting period (interim or annual) ending after December 15, 2008, with earlier application encouraged. The Company adopted this FSP effective January 1, 2009. The adoption of the FSP had no impact on the Company's results of operations, financial condition or cash flows. In December 2008, the FASB issued FSP No. FAS 132(R)-1, "Employers' Disclosures about Postretirement Benefit Plan Assets" ("FSP FAS 132(R)-1"). FSP FAS 132(R)-1 requires additional fair value disclosures about employers' pension and postretirement benefit plan assets consistent with guidance contained in SFAS 157. Specifically, employers will be required to disclose information about how investment allocation decisions are made, the fair value of each major category of plan assets and information about the inputs and valuation techniques used to develop the fair value measurements of plan assets. This FSP is effective for fiscal years ending after December 15, 2009. The Company does not expect the adoption of FSP FAS 132(R)-1 will have a material impact on its financial condition or results of operation. In September 2008, the FASB issued exposure drafts that eliminate qualifying special purpose entities from the guidance of SFAS No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities," and FASB Interpretation 46 (revised December 2003), "Consolidation of Variable Interest Entities - an interpretation of ARB No. 51," as well as other modifications. While the 10 proposed revised pronouncements have not been finalized and the proposals are subject to further public comment, the Company anticipates the changes will not have a significant impact on the Company's financial statements. The changes would be effective March 1, 2010, on a prospective basis. In June 2008, the FASB issued FASB Staff Position EITF 03-6-1, determining whether instruments granted in share-based payment transactions are participating securities, ("FSP EITF 03-6-1"). FSP EITF 03-6-1 addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting, and therefore need to be included in the computation of earnings per share under the two-class method as described in FASB Statement of Financial Accounting Standards No. 128, "Earnings per Share." FSP EITF 03-6-1 is effective for financial statements issued for fiscal years beginning on or after December 15, 2008 and earlier adoption is prohibited. We are not required to adopt FSP EITF 03-6-1; neither do we believe that FSP EITF 03-6-1 would have material effect on our consolidated financial position and results of operations if adopted. In May 2008, the Financial Accounting Standards Board ("FASB") issued SFAS No. 163, "Accounting for Financial Guarantee Insurance Contracts-and interpretation of FASB Statement No. 60". SFAS No. 163 clarifies how Statement 60 applies to financial guarantee insurance contracts, including the recognition and measurement of premium revenue and claims liabilities. This statement also requires expanded disclosures about financial guarantee insurance contracts. SFAS No. 163 is effective for fiscal years beginning on or after December 15, 2008, and interim periods within those years. SFAS No. 163 has no effect on the Company's financial position, statements of operations, or cash flows at this time. In May 2008, the Financial Accounting Standards Board ("FASB") issued SFAS No. 162, "The Hierarchy of Generally Accepted Accounting Principles". SFAS No. 162 sets forth the level of authority to a given accounting pronouncement or document by category. Where there might be conflicting guidance between two categories, the more authoritative category will prevail. SFAS No. 162 will become effective 60 days after the SEC approves the PCAOB's amendments to AU Section 411 of the AICPA Professional Standards. SFAS No. 162 has no effect on the Company's financial position, statements of operations, or cash flows at this time. In March 2008, the Financial Accounting Standards Board, or FASB, issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities--an amendment of FASB Statement No. 133. This standard requires companies to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under Statement 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. This Statement is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. The Company has not yet adopted the provisions of SFAS No. 161, but does not expect it to have a material impact on its consolidated financial position, results of operations or cash flows. 11 h. Basic Income (Loss) Per Share In accordance with SFAS No. 128-"Earnings Per Share", the basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. At July 31, 2009, the Company has no stock equivalents that were anti-dilutive and excluded in the earnings per share computation. i. Cash and Cash Equivalents For purposes of the statement of cash flows, the company considers all highly liquid investments purchased with maturity of three months or less to be cash equivalents. As of July 31, 2009 the company had no cash. j. Liabilities Liabilities are made up of current liabilities and long-term liabilities. Current liabilities include accounts payable of $10,200. There is a long term liability of $6,316 outstanding for the company. The loan of $6,316 is a related part loan as it is lent from a director. The loan is non-interest bearing loan with no fixed due date. Share Capital a) Authorized: 75,000,000 common shares with a par value of $0.001 b) Issued: The authorized capital of the Company is 75,000,000 common shares with a par value of $0.001 per share. In February 2008, the Company issued 30,000,000 shares of common stock at a price of $0.0001 per share for total cash proceeds of $3,000. In February 2008, the Company issued 21,000,000 shares of common stock at a price of $0.001 per share for total cash proceeds of $21,000. In March 2008, the Company also issued 1,500,000 shares of common stock at a price of $0.005 per share for total cash proceeds of $7,500. On February 1, 2009, the Company issued 1,000,000 shares of common stock at a price of $0.021 per share for total cash proceeds of $21,000. On March 15, 2009, the Company also issued 100,000 shares of common stock at a price of $0.075 per share for total cash proceeds of $7,500. On March 10, 2009, the Company completed a forward stock split of its common stock on a ratio of ten shares for every one share of the Company. The record date of the forward stock split was February 27, 2009, the payment date of the forward split was March 9, 2009, and the ex-dividend 12 date of the forward split was March 10, 2009. The forward split was payable as a dividend, thereby requiring no action by shareholders, nor any amendment to the articles of incorporation of the Company. On May 15, 2009, the Company issued a total of 3,020,000 shares of common stock at an average price of $0.01 per share for the services provided to the Company during the three months ended July 31, 2009. There are no preferred shares authorized. The Company has issued no preferred shares. The Company has no stock option plan, warrants or other dilutive securities. k. Advertising The Company expenses advertising as incurred. To this date, the Company has incurred no advertising expenses. l. Property Note The Company does not own or rent any property. The office space is contributed by a director at no charge. NOTE 3 - REALATED PARTY As of July 31, 2009 the Company owes a director $6,316 for expenses paid on behalf of the Company. The amount is non interest bearing and due upon demand. Imputed interest is not considered to material. NOTE 4 - GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, the Company has accumulated a loss and is new. This raises substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from this uncertainty. As shown in the accompanying financial statements, the Company has incurred a net loss of $101,766 for the period from inception to July 31, 2009 and has not generated any revenues. The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations from the development of acquisitions. Management has plans to seek additional capital through a private placement and public offering of its common stock. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. 13 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION. FORWARD LOOKING STATEMENTS The information in this discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements involve risks and uncertainties, including statements regarding Air Transport Group Holdings, Inc (the "Company") capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms or other comparable terminology. Actual events or results may differ materially. In evaluating these statements, you should consider various factors, including the risks outlined below, and, from time to time, in other reports the Company files with the SEC. These factors may cause the Company's actual results to differ materially from any forward-looking statement. The Company disclaims any obligation to publicly update these statements, or disclose any difference between its actual results and those reflected in these statements. The information constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. As used in this quarterly report, the terms "we," "us," "our," and "our company" mean Air Transport Group Holdings, Inc. unless otherwise indicated. All dollar amounts in this quarterly report are in U.S. dollars unless otherwise stated. OVERVIEW Air Transport Group Holdings, Inc ("the Company") wascompany incorporated under the laws of British Columbia, Canada, whereby the ~~State of Nevada, U.S. on November 26, 2007 under the name Azure International, Inc. On October 30, 2008, and effective as~~Company acquired all of the ~~same date,~~issued and outstanding shares of WFS Pharmagreen Inc. in exchange for 37,704,500 shares of common stock of the Company. Upon completion of this transaction, the shareholders of WFS Pharmagreen hold 95.5% of voting control of the Company.

Immediately prior to closing of the Agreement, the majority shareholder of the Company ~~filed Articles~~was also the majority shareholder of ~~Merger ("Articles") with the Secretary of State of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc.~~WFS. As a result of the ~~merger,~~common ownership upon closing of the transaction, the acquisition was considered a common-control transaction and was outside the scope of the business combination guidance in ASC 805-50. The entities are deemed to be under common control as of February 27, 2018, which was the date that the majority shareholder acquired control of the Company and, therefore, held control over both companies. On May 2, 2018, the Share Exchange Agreement was effected. In connection with this transaction, the Company changed its name on May 8, 2018 to ~~Air Transport Group Holdings,~~Pharmagreen Biotech Inc. ~~STRATEGY Air Transport Group Holdings~~and changed its year end from April 30th to September 30th.

Our principal executive offices are temporarily located at 2987 Blackbear Court, Coquitlam, British Columbia, Canada. Our telephone number is (702-803-9404). Our internet address is www.pharmagreen.ca.

On August 7, 2020, our company (including our subsidiaries) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the ~~business~~United States Bankruptcy Court for the District of ~~acquiring aviation, travel, and leisure companies. By acquiring multiple small to mid size companies AITG plans to increase its efficiencies~~Nevada, Case No. 20-13886.

On October 9, 2020, a stay order was lifted by consolidate management expenses, negotiate preferred rates with vendors, and increasing its asset base. RESULTS OF OPERATIONS FOR THE PERIOD ENDED JULY 31, 2009 The accompanying financial statements show thata United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company ~~has incurred a net loss of $30,415~~from its Chapter 11 bankruptcy proceedings and protection.

We expect to continue to incur losses for at least the ~~three month period ended July 31, 2009 and has not yet generated any revenues that can offset operating expenses.~~next 12 months. We anticipate that we will not earn revenues until such time as we have further advanced the development of our company. We are presently in the development stage of our business and we can provide no assurance of our ability to obtain future profitable operation of our cooperation. 14 ~~LIQUIDITY AND FINANCIAL CONDITION Based on our current operating plan, we~~ do not expect to generate revenue that is sufficient to cover our expenses, ~~for at least the next year. In addition,~~and we do not have sufficient cash and cash equivalents to execute our plan of operations for at least the next ~~year.~~twelve months. We will need to obtain additional financing, through equity security sales, debt instruments and private financing, to ~~operate~~conduct our day-to-day operations, and to fully execute our business ~~for the next twelve months.~~plan. We ~~will~~plan to raise the capital necessary to fund our business through the sale of equity securities, debt instruments or private financing. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. This report does not reflect all the adjustments that may be necessary if the Company is unable to continue as a going concern.

Table of Contents

Our Current Business

Pharmagreen Biotech Inc. (the “Company”) was incorporated under the laws of the State of Nevada on November 26, 2007. The Company is headquartered in Coquitlam, British Columbia. The Company’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of high CBD hemp and other flora and offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American high CBD hemp, Cannabis and agriculture sectors.

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. However, if the Company is unable to raise additional capital in the near future, due to the Company’s liquidity problems, management expects that the Company will need to curtail operations, liquidate assets, seek additional capital on less favourable terms and/or pursue other remedial measures. These consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company has decided that immediate business development in the hemp and cannabis industries provides a much greater opportunity in the United States. The project at Deroche has been placed on hold while the Company moves forward to build out a similar infrastructure planned for Deroche within the United States.

Subsequent to June 30, 2021, more specifically July 25th 2021, the Company entered into a Memorandum of Understanding to acquire all the assets and cannabis business operation (includes 12 acres property, structure and cannabis licenses, existing sales channels and distribution networks) from a private ~~placement~~company situated in Northern California. Upon reaching a definitive agreement, the Company intends to further develop a state-of-the-art flowering greenhouse of approximately 12,000 square feet or the maximum allowed by California State and ~~public offering~~Regional County. The acquisition price is $2.4 million to be paid through a combination of cash and shares. The Company also has an option from the seller to acquire an additional 120 acres or more of land for business expansion and development. The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction. Thus, there is no assurance that the Company will ever enter into, and consummate, a definitive agreement with respect to the contemplated transaction.

Capital Resources and Liquidity

Our auditors have issued a “going concern” opinion for our year ended September 30, 2020, meaning that there is substantial doubt if we can continue as an on-going business unless we obtain additional capital. No substantial revenues from our planned business model are anticipated until we have completed financing the Company. As at June 30, 2021, we had a working capital deficit of $1,802,567, and an accumulated deficit of $10,867,990. During the nine months ended June 30, 2021, we have not earned any revenues from our operations and used cash of $151,237 for our operating activities.

Table of Contents

We need to seek capital from resources such as the sale of private placements in the Company’s common ~~stock. Additional financing, whether through public or private equity~~stock or debt financing, ~~arrangements~~which may not even be available to the Company. However, if such financing were available, because we are a, early-stage company with ~~shareholders~~no or ~~other sources~~limited operations to date, it would likely have to pay additional costs associated with such financing and in the case of high risk loans be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such financing. If the Company cannot raise additional proceeds via such financing, it may be required to cease business operations.

As of June 30, 2021, we had $19,218 in cash as compared to $12,196 in cash and prepaid expenses and deposits of $253,754 as of September 30, 2020. As of the date of this Form 10-Q, the current funds available to the Company will not be sufficient to fund ~~operations,~~the expenses related to maintaining our planned operations. We are in the process of seeking additional equity financing in the form of private placements, loans and registration statements to fund our intended business operations.

Management believes that if subsequent private placements are successful or we are successful in raising funds from registered securities, we will generate sales revenue within twelve months thereof. However, additional equity financing may not be available to us on acceptable terms or ~~if available, may be on terms unacceptable~~at all, and thus we could fail to ~~us. Our ability~~satisfy our future cash requirements.

We do not anticipate researching any further products nor the purchase or sale of any significant equipment. We also do not expect any significant additions to ~~maintain sufficient liquidity is dependent on our ability to raise additional capital. If we issue additional equity securities to raise funds,~~ the ~~ownership percentage~~number of ~~our existing shareholders would be reduced. New investors may demand rights, preferences or privileges senior to those~~employees.

Results of ~~existing holders of our common stock. Debt incurred by us would be senior to equity~~Operations

Three Months Ended June 30, 2021

We had $nil in revenue for the three months ended June 30, 2021 and 2020.

Total expenses in the ~~ability~~three months ended June 30, 2021 were $232,380 as compared to total expenses for the three months ended June 30, 2020 of $86,914. The net increase in expenses during the current period is mainly due to an increase in consulting fees from $30,108 in 2020 to $190,794 in 2021, which was mainly related to a production agreement entered into with New to the Street Group LLC on May 13, 2021.

We incurred a comprehensive loss of $1,377,795 during the three months ended June 30, 2020, compared to a comprehensive loss of $155,360 during the three months ended June 30, 2021. The decrease in comprehensive loss in 2021 was mainly attributable to a change in fair value of derivative liabilities from a loss of $1,187,033 in 2020 to a gain of $101,418 in 2021, as the Company had significantly more convertible debt ~~holders~~in the prior year which resulted in more fluctuations of the derivative liability due to ~~make claims~~the floating rates attached to the conversion rights to the convertible debt.

During the three months ended June 30, 2021 and 2020, we incurred a net loss of $nil and $0.02 per share respectively.

Nine Months Ended June 30, 2021

We had $nil in revenue for the nine months ended June 30, 2021 and 2020.

Total expenses in the nine months ended June 30, 2021 were $470,953 as compared to total expenses for the nine months ended June 30, 2020 of $354,632. The net increase in expenses during the current period is mainly due to an increase in consulting fees from $153,999 in 2020 to $296,987 in 2021, which was mainly related to a production agreement entered into with New to the Street Group LLC on ~~our assets.~~May 13, 2021.

We incurred a comprehensive loss of $3,769,058 during the nine months ended June 30, 2021, compared to a comprehensive loss of $1,568,200 during the nine months ended June 30, 2020. The ~~terms~~increase in comprehensive loss during 2021 was mainly attributable to interest and finance costs of ~~any debt issued could impose restrictions~~$673,124 compared to $45,000 in 2020, and a loss on ~~our operations. If adequate funds are not available~~change in fair value of derivative liabilities from $1,347,031 in 2020 to ~~satisfy either short or long-term capital requirements, our operations~~$3,083,420 in 2021, offset by a loss on settlement of convertible notes from $38,411 in 2020 to a gain of $613,526 in 2021.

During the nine months ended June 30, 2021, and ~~liquidity could be materially adversely affected~~2020, we incurred a net loss of $0.01 and ~~we could be forced to cease operations. OFF-BALANCE SHEET ARRANGEMENTS We have~~$0.02 per share, respectively.

Table of Contents

Off-balance Sheet Arrangements

The Company has no ~~significant~~ off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on ~~our financial condition, changes in~~the company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that isare material to ~~stockholders. INFLATION In~~investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the ~~opinion~~company is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of ~~management, inflation has~~the Exchange Act and are not had a material effect on our operations. RESEARCH AND DEVELOPMENT EXPENDITURES We have not incurred any research or development expenditures since our incorporation. PATENTS AND TRADEMARKS We do not own, either legally or beneficially, any patent or trademark. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Not applicable. ITEMrequired to provide the information required under this item.

Item 4. ~~CONTROLS AND PROCEDURES. EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES We evaluated the effectiveness~~Controls and Procedures.

Evaluation of ~~our disclosure~~Disclosure Controls and Procedures

Disclosure controls and procedures ~~as of the date of this report. This evaluation was conducted by our President and Chief Executive Officer, Arnold Leonora. Disclosure controls~~ are controls and other procedures that are designed to ensure that information ~~that we are~~ required to ~~disclose~~be disclosed in ~~the~~our reports ~~we file pursuant to the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported. 15~~ ~~Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f)~~filed or ~~15d-15(f) promulgated~~submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as ~~amended,~~appropriate, to allow timely decisions regarding required disclosure.

In connection with this quarterly report, as ~~a process designed~~required by orRule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of ~~the company's~~our company’s management, including our company’s principal executive officer and principal financial ~~officers~~officer. Based upon that evaluation, our company’s principal executive officer and ~~effected by the company's board~~principal financial officer concluded that as of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policiesJune 30, 2021 our disclosure controls and procedures ~~that: - Pertain~~were not effective due to the ~~maintenance~~existence of ~~records that~~material weaknesses in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; - Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and - Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements. Because of its inherent limitations,our internal ~~control~~controls over financial ~~reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of~~reporting.

Changes in Internal Control Over Financial Reporting

There were no changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. As of July 31, 2009 management assessed the effectiveness of our internal control over financial reporting ~~based on the criteria for effective internal control over financial reporting established~~(as defined in ~~Internal Control--Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"~~Rule 13a-15(f) or 15d-15(f)) ~~and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that,~~ during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below. This was due to deficienciesquarter ended June 30, 2021 that existed in the design or operation of our internal controls over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses. The matters involving internal controls and procedures that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) inadequate segregation of duties consistent with control objectives; and (3) ineffective controls over period end financial disclosure 16 and reporting processes. The aforementioned material weaknesses were identified by our Chief Executive Officer in connection with the review of our financial statements as of July 31, 2009. Management believes that the material weaknesses set forth in items (2) and (3) above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods. MANAGEMENT'S REMEDIATION INITIATIVES In an effort to remediate the identified material weaknesses and other deficiencies and enhance our internal controls, we have initiated, or plan to initiate, the following series of measures: We will create a position to segregate duties consistent with control objectives and will increase our personnel resources and technical accounting expertise within the accounting function when funds are available to us. And, we plan to appoint one or more outside directors to our board of directors who shall be appointed to an audit committee resulting in a fully functioning audit committee who will undertake the oversight in the establishment and monitoring of required internal controls and procedures such as reviewing and approving estimates and assumptions made by management when funds are available to us. Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of outside directors on our Board. We anticipate that these initiatives will be at least partially, if not fully, implemented by December 31, 2009. Additionally, we plan to test our updated controls and remediate our deficiencies by December 31, 2009. CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING There was no change in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or isare reasonably likely to materially affect, our internal controls over financial reporting. ~~PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS. We~~

Saturna Group Chartered Professional Accountants LLP, our independent auditors, are not required to and have not performed an assessment of our internal controls over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

On July 22, 2020, the Company received a preliminary statement of claim from a convertible note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the plaintiff has requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal amount of $78,000 for a total sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note.

On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company from its Chapter 11 bankruptcy proceedings and protection. The lifting of the stay order further allowed the convertible note holders to convert thereby increasing the number of shares issued and outstanding.

On October 29, 2020 a second note holder filed a statement of claim. This lender, as of December 24, 2020, has completely converted the full amount of the note of $100,000, interest of $8,689.80 and penalty and fees aggregating $19,500.

Also, as mentioned above, the Company filed voluntary petitions for reorganization under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. The Company’s filing with the Court was designated as Case No. 20-13886. During the pendency of this matter, the Company has also filed motions with the Court seeking authorization to continue to operate its businesses as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. Due to the stay order mentioned, the Company did not file a plan of reorganization with the Court for approval.

On March 12, 2021, the Company entered into a settlement agreement with the convertible noteholder that had filed a preliminary statement of claim on July 22, 2020. Pursuant to the agreement the Company was required to honor various conversion notices and the noteholder agreed to wave all principal, interest and penalties incurred.

On March 10, 2021, the promissory note holder referred to in Note 4 (a) of the accompanying financial statements filed a Notice of Motion For Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court.

Except as mentioned in the preceding paragraphs, there are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or stockholder is a party adverse to ~~any~~the Company or has a material ~~legal proceedings and~~interest adverse to ~~our knowledge, no such proceedings are threatened or contemplated. ITEM~~the Company.

Item 1A. ~~RISK FACTORS. Not applicable. 17~~ ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. Not applicable. ITEM 3. DEFAULTS UPON SENIOR SECURITIES. None. ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. No matters were submitted to our security holders forRisk Factors.

As a vote during the period ending January 31, 2009. ITEM 5. OTHER INFORMATION. None. ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K. Exhibit Number Description of Exhibit - -------------- ---------------------- 31.1 Certification by Chief Executive Officer and Chief Financial Officer required by“smaller reporting company,” as defined in Rule ~~13a-14(a) or Rule 15d-14(a)~~12b-2 of the Exchange Act, ~~promulgated pursuant~~we are not required to ~~Section 302~~provide the information called for by this Item.

Item 2. Unregistered Sales of Securities and Use of Proceeds.

During the three months ended June 30, 2021, we issued a total of 6,961,250 units of our securities (each unit is comprised of one share of common stock and one warrant purchase an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months) for a total of $69,613 in cash. These funds were used for operating expenses.

Item 3. Defaults Upon Senior Securities.

The commencement of the ~~Sarbanes-Oxley Act~~Chapter 11 Cases discussed above constituted an event of ~~2002, filed herewith 32.1 Certification by Chief Executive Officer and Chief Financial Officer, required by Rule 13a-14(b) or Rule 15d-14(b)~~default under certain of the ~~Exchange Act and Section 1350 of Chapter 63 of Title 18~~Company’s debt instruments, including various convertible notes, which resulted in automatic acceleration of the ~~United States Code, promulgated pursuant to Section 906~~Company’s obligations under such debt instruments. As of the ~~Sarbanes-Oxley Act~~date of ~~2002~~this Quarterly Report, we are in default under two separate convertible debt instruments.

Item 4. Mine Safety Disclosure.

N/A

Item 5. Other Information.

None

Table of Contents

Item 6. Exhibits.

The following documents are filed ~~herewith 18~~ as a part of this report or are incorporated by reference to previous filings, if so indicated:

Exhibit Number		Description

2.1		Articles of Incorporation and Bylaws dated November 26, 2007 as previously filed with the SEC on March 20, 2019

2.2		Articles of Merger dated, October 30, 2008 (Azure International, Inc./ Air Transport Group Holding, Inc. as previously filed with the SEC on March 20, 2019

2.10		Equity Purchase Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019

2.11		Registration Rights Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019

31.1		Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

31.2		Certification of Chief Executive Officer Pursuant to Rule 13a–14(a) or 15d-14(a) of the Securities Exchange Act of 1934**

32.1		Certification of Chief Executive Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Principal Financial Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

* Included in Exhibit 31.1

** Included in Exhibit 32.1

Table of Contents

SIGNATURES ~~In accordance with~~*

Pursuant to the requirements of the Securities ~~and~~ Exchange Act of 1934, the ~~Registrant~~registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: October 15, 2009 SIGNATURE TITLE DATE --------- ----- ---- By: /s/ Arnold Leonora President and Director October 15, 2009 ----------------------------- Arnold Leonora 19

	Pharmagreen Biotech Inc.

Dated August 16, 2021	By:	/s/ Peter Wojcik
		Peter Wojcik
		President and Director Principal Executive Officer

	By:	/s/ Terry Kwan
		Terry Kwan
		Principal Accounting Officer

	PART I—FINANCIAL INFORMATION
Item 1.	Financial Statements.	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	25
Item 4.	Controls and Procedures.	25

	PART II—OTHER INFORMATION
Item 1.	Legal Proceedings.	26
Item 1A.	Risk Factors.	26
Item 2.	Unregistered Sales of Securities and Use of Proceeds.	26
Item 3.	Defaults Upon Senior Securities.	26
Item 4.	Mine Safety Disclosure.	26
Item 5.	Other Information.	26
Item 6.	Exhibits.	27
	SIGNATURES	28